Boston Scientificvs.GE HealthCare
BSX vs GEHC · both in Medtech & devices, part of the Medicine, pharma & life science value chain: Medical equipment and devices, from surgery and cardiology to robotics.
Boston Scientific is about 2.1× larger than GE HealthCare by market cap; GE HealthCare trades at the lower P/E (14.6 vs 16.5); year to date, GE HealthCare leads (−21.2% vs −56.4%).
Side by side
| BSX | GEHC | |
|---|---|---|
| Market cap | $60.7B | $29B |
| Price | $42.04 | $64.22 |
| Today | +1.1% | −0.7% |
| Return YTD | −56.4% | −21.2% |
| Return 1Y | −56.6% | −13.2% |
| Since June 26, 2026 | −5.0% | −2.3% |
| P/E | 16.5 | 14.6 |
| P/S | 2.9 | 1.4 |
| P/B | 2.4 | 2.6 |
Data as of 2026-10-08 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
Boston ScientificBSX
Cardiology drives the growth, particularly electrophysiology, where Farapulse sits, and structural heart treatment. Endoscopy and urology cover the rest of the range.
Full BSX profile →GE HealthCareGEHC
Imaging is the core: CT and MRI systems, plus ultrasound. Patient monitoring equipment and contrast agents round out a range sold worldwide.
Full GEHC profile →More BSX & GEHC comparisons
Other head-to-heads in the Medtech & devices segment.